Study name and trial number	Sponsors	Country / Sample size	Criteria	Phase	Study arms Intervention                              Control		Duration / Primary outcome
Individually randomized controlled trials
TBTC Study 26:Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection. NCT00023452	CDC Dept. of Veteran Affairs	USA Brazil Canada Spain N˜8000 (Enrolling)	?2 yrs Not pregnant TST+ at high risk of developing TB HIV+ close contacts of culture + TB patients	III	RPT/INH once weekly for 3 months	INH for 9 months	?18yrs: Culture+ TB <18yrs:  Culture+ or probable (clinical) TB
Tuberculosis Prevention for HIV Infected Adults. NCT00057122	Johns Hopkins University and NIAID	South Africa N˜1148 (enrolment closed)	Age?18 yrs HIV‐+ TST ?5mm CXR negative for TB	III	* RPT/INH for 3 months and observed weekly * RIF/INH for 3 months and observed twice weekly * Continuous INH self supervised	INH self super‐vised for 6 months	1‐4 yrs follow up Active TB
A Randomized, Placebo‐Controlled Study of Limited Vs. Continuous Isoniazid Tuberculosis Preventive Therapy for HIV‐Infected Persons in Botswana NCT00164281	CDC Botswana MOH USAID	Botswana N˜1800 (Enrolling)	?18yrs HIV+ TST + or not pregnant	IV	Continuous INH	INH for 6 months	Accrual 1yr, follow‐up  24‐36 months Active PTB or ETB
Randomized Controlled Trial of 4 Months Rifampin Versus 9 Months INH for the Treatment of Latent TB. NCT00170209	McGill University	Canada Number not specified	Age?15yrs TST + Not pregnant HIV+ or other immune suppressed conditions	IV	RIF for 4 months	INH for 9  months	April 2004 ‐ July 2007
An efficacy study of two preventive therapy studies in HIV‐infected persons in India. NCT00351702	Tuberculosis Research Centre, India USAID	India N=650 (enrolment closed)	?15yrs HIV +	III	* ETH/IINH for 6 months	INH for 36 months	Follow up 5 yrs Active TB Mortality